Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Aspirin for Prevention of Recurrent Preeclampsia

Am J Obstet Gynecol; ePub 2017 Apr 25; Tolcher, et al

Following the release of the US Preventive Services Task Force (USPSTF) recommendation for aspirin for preeclampsia prevention, rates of recurrent preeclampsia among women with a history of preeclampsia decreased, a recent study found. The retrospective cohort study utilized a 2-hospital, single academic institution database from August 2011 through June 2016. Researchers found:

  • 17,257 deliveries occurred during the study period.
  • 417 women had a documented history of prior preeclampsia; 284 before and 133 after the release of the USPSTF recommendation.
  • The prevalence of type 1 diabetes was increased in the after period, but overall rates of pregestational diabetes were similar.
  • Risk factors for recurrent preeclampsia included maternal age >35 years, type 2 diabetes, and chronic hypertension.
  • Risk of recurrent preeclampsia was decreased by 30% in the after group.

Citation:

Tolcher MC, Chu DM, Hollier LM, et al. Impact of USPSTF recommendations for aspirin for prevention of recurrent preeclampsia. [Published online ahead of print April 25, 2017]. Am J Obstet Gynecol. doi:10.1016/j.ajog.2017.04.035.